Impending central retinal vein occlusion in patient with idiopathic cutaneous leukocytoclastic vasculitis

Abstract

Purpose To report a case of impending central retinal vein occlusion (CRVO) associated with idiopathic cutaneous leukocytoclastic vasculitis (LCV) that demonstrated significant resolution following treatment with intravenous (IV) methylprednisolone. Observations A 27-year-old man presented to a tertiary Uveitis Clinic with a five-day history of blurry vision in the right eye (OD). He had a history of a purpuric rash and arthralgias five years ago and a biopsy-confirmed diagnosis of LCV controlled with colchicine two years ago in India. Recently, he presented with a recurrent rash and severe abdominal pain. After being evaluated by rheumatology and gastroenterology, he was placed on Helicobacter pylori treatment and high dose oral prednisone, which improved his skin and gastrointestinal symptoms. At the first ophthalmic exam, his systemic findings included lower extremity purpura. His best-corrected visual acuity (BCVA) was 20/20 in both eyes (OU). Slit-lamp examination revealed no cells or flare in OU. Dilated fundus exam showed mild enlarged, tortuous veins, optic nerve hemorrhage, and intraretinal hemorrhages temporal to the macula in OD. Spectral-domain optical coherence tomography (SD-OCT) demonstrated multiple hyper-reflective, plaque-like lesions involving the inner nuclear layer, consistent with paracentral acute middle maculopathy (PAMM). The patient was diagnosed with impending central retinal vein occlusion (CRVO) in OD. Laboratory evaluations were unremarkable. Aspirin was initially started for the patient but was later held due to the worsening of retinal hemorrhage and retinal vein tortuosity at the one-week follow-up. The patient then received three doses of intravenous methylprednisolone, followed by systemic oral prednisone and mycophenolate mofetil. One month later, retinal hemorrhages, venous stasis, and skin manifestations resolved. Conclusion and importance Ocular involvement in LCV is rare and may present with different manifestations. The index case is the first report of impending CRVO in a patient with idiopathic LCV and without any other known risk factors for CRVO. Our report not only describes the unique course of LCV-related ocular involvement, but also introduces and underscores a potentially effective therapeutic plan.

Assessing the impact of aging and blood pressure on dermal microvasculature by reactive hyperemia optical coherence tomography angiography

“…Future studies should consider the in vivo assessment of vessel diameter by OCT-A and RH-OCT-A to improve the diagnosis of cutaneous vasculitis, an inflammation of the small blood vessels of the skin, which is classified by the size of vessels affected 46 . In addition, histopathology is limited to only providing morphological information, whereas OCT-A and RH-OCT-A have been shown to provide functional microvasculature information in response to local stimuli such as topical drugs, mechanical distortion, and temperature changes 16 , 47 .…”

Swept-source optical coherence tomography angiography metrics of retinal ischaemic perivascular lesions in patients being evaluated for carotid artery stenosis and controls

“…Our finding of unchanged VT in any comparison supports the idea that RIPLs reflect chronic lesions similar to PAMM lesions. Prior case reports of PAMM have demonstrated that qualitative changes in tortuosity in PAMM generally follow a pattern of occasional acute increases in tortuosity21 22 that sometimes progressively worsen23 but that eventually improve 24…”

Henle fiber layer hemorrhage as the first manifestation of factor V Leiden homozygous mutation

“…Fluorescein angiography displays no stops or delays in vein vascular flow when performed. 9 HFL hemorrhages in recent case series have shown spontaneous resolution within three months in almost half of the patients available, although it may cause ellipsoid zone disruption or residual hyperreflective bands crossing the vertical plane of the retina. 2 However, patients with decreased visual acuity affecting daily life activities or those with ellipsoid zone involvement may benefit from recombinant tissue plasminogen activator (r-TPA), sulfur hexafluoride (SF6) and anti-vascular endothelial growth factor (anti-VEGF), with or without vitrectomy, to displace the hemorrhages from the fovea.…”